

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The information set out below in this announcement is provided for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company.

Guanze Medical Information Industry (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2427)

(1) CLARIFICATION ANNOUNCEMENT IN RELATION TO RULE 3.7 ANNOUNCEMENT, RULE 13.09 OF THE LISTING RULES AND INSIDE INFORMATION PROVISIONS AND (2) CONTINUED SUSPENSION OF TRADING

Reference is made to the announcement of the Company dated 27 January 2026 in relation to, among other things, the unusual price and trading volume movements and the possible general offer for the Shares (the “**Rule 3.7 Announcement**”). Unless otherwise defined herein, all capitalised terms used herein shall have the same meanings as defined in the Rule 3.7 Announcement.

The Company would like to update the investors that on 28 January 2026, a sale and purchase agreement was entered into between Meng A Capital and FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED (the “**Purchaser**”) pursuant to which Meng A Capital has conditionally agreed to sell, and the Purchaser has conditionally agreed to purchase 699,164,575 Shares, representing approximately 73.60% of the total issued share capital of the Company (the “**Possible Disposal**”). The Purchaser is ultimately beneficially owned as to 94% by Mr. Cheung Chun (張峻) and as to 6% by Ms. Tao Meiying (陶美縈). The Company will make further announcement(s) pursuant to Rule 3.5 of the Takeovers Code (the “**Rule 3.5 Announcement**”) as soon as practicable.

The Company would also like to clarify that the following paragraph should have been included in the Rule 3.7 Announcement:

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the Shares on the Stock Exchange has been suspended with effect from 1:00 p.m. on 26 January 2026 and will remain suspended until further notice.

Save for the above amendment, no other changes are made in the Rule 3.7 Announcement.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the Shares on the Stock Exchange has been suspended with effect from 1:00 p.m. on 26 January 2026 pending the publication of the Rule 3.5 Announcement.

WARNING

Shareholders and potential investors of the Company shall be aware that the Possible Disposal may or may not complete. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company, and if they are in any doubt about their position, they should consult their professional advisers.

By order of the Board
Guanze Medical Information Industry (Holding) Co., Ltd.
Meng Xianzhen
Chairman of the Board

Hong Kong, 29 January 2026

As at the date of this announcement, the executive Directors are Mr. Meng Xianzhen and Mr. Guo Zhenyu, the non-executive Director is Ms. Meng Cathy, and the independent non-executive Directors are Dr. Zhao Bin, Dr. Chang Shiwang and Dr. Wong Man Hin Raymond.

The Directors jointly and severally accept full responsibility for the accuracy of information contained in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.